MARKETS / NYSE / RVTY

NYSE · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP

Revvity, Inc. RVTY

18 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$2.9B

▲ 3.7% YoY

Net income

$241.2M

▼ 10.8% YoY

Free cash flow

$509.4M

▼ 6.0% YoY

In brief

What this company does

Revvity provides health science solutions, technologies, expertise and services that support workflows from discovery to development, and from diagnosis to cure. The company is headquartered in Waltham, Massachusetts, and markets its products and services in more than 160 countries. As of December 28, 2025, it employed approximately 11,000 people. Revvity reports its business in two segments, Life Sciences and Diagnostics. The Life Sciences segment provides products, solutions, software and services for workflows across the drug discovery and development pipeline. The Diagnostics segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals, with a focus on reproductive health, immunodiagnostics and emerging market diagnostics.

Written from the business description in REVVITY, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.9B

Revenue, FY2025 · full 18-year series below

Revenue $B Net income $B

FY2025 · Revenue 2.9 · Net income 0.2

Compound annual growth

Revenue

−4.8%

+1.4%

+3.1%

+3.5%

Net income

−24.9%

−19.8%

+1.3%

−3.2%

EPS, diluted

−22.8%

−20.4%

+1.0%

−3.1%

Dividend / share

+0.0%

Returned to shareholders

+94.5%

+86.2%

+23.0%

+14.9%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +1.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

8 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 12.5% · Net 8.4%

ROE

FY2025 · ROE 3.2%

Gross margin—

Operating margin12.5%

Net margin8.4%

Return on assets2.0%

EBITDAUSD 762.0M

Each USD of equity produced 3 cents of profit this year.

Cash & shareholders

USD 853.6M

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 0.5

Net buybacks $M Dividends $M

FY2025 · Dividends 32.8 · Net buybacks 820.8

Dividends paidUSD 32.8M

Net buybacksUSD 820.8M

Share of profit353.9%

Consecutive raises—

USD 32.8M in dividends and USD 820.8M in buybacks — 354% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 12.2B

EquityUSD 7.3B

CashUSD 919.9M

Gross debtUSD 3.2B

Net debtUSD 2.3B

Current ratio1.68×

Net debt stands at 32% of equity.

The 18-year record

18 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue $B	2.9	2.8	2.8	3.3	3.8	2.7	2.9	2.8	2.3	2.1	2.1	2.1	2.2	2.1	1.9	1.7	1.6	1.7
Operating income $B	0.4	0.3	0.3	0.7	1.3	0.9	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.1	0.1	0.2	0.1	0.1
EBITDA $B	0.8	0.8	0.7	1.2	1.6	1.1	0.6	0.5	0.4	0.4	0.4	0.3	0.4	0.2	0.2	0.2	0.2	0.2
Income tax $B	0.0	0.0	0.0	0.1	0.3	0.2	0.0	0.0	0.1	0.0	0.0	−0.0	−0.0	−0.0	0.1	0.0	0.0	0.0
Net income $B	0.2	0.3	0.7	0.6	0.9	0.7	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.0	0.4	0.1	0.1
Free cash flow $B	0.5	0.5	0.0	0.6	1.3	0.8	0.3	0.2	0.2	0.3	0.3	0.3	0.1	0.1	0.2	0.1	0.1	0.2
EPS, diluted $	2.07	2.20	5.55	4.50	8.08	6.49	2.04	2.13	2.64	2.12	1.87	1.39	1.47	0.61	0.07	3.31	0.70	1.07
Dividend / sh $	0.28	0.28	0.28	0.28	·	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	·	·
Payout %	14	13	5	6	3	4	14	13	11	13	15	20	19	46	416	8	40	26
ROE %	3.2	3.5	9.1	7.8	17.3	22.2	8.4	9.4	12.6	11.0	10.2	7.8	8.5	3.7	0.4	22.0	5.1	8.1
Shares out B	0.11	0.12	0.12	0.13	0.13	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.12	0.11	0.12	0.12	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures · 8 divergences in 78 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 8 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 15 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures8 divergent

ActivityLaboratory Analytical Instruments

Listed onNYSE

Incorporated inMassachusetts

Fiscal year endsDecember 29

Data on record since2008